Kornimate/medical-research-clean huggingface dataset:
serous endometrial intraepithelial carcinoma (seic): prospective registration study

Conditions: Serous Endometrial Intraepithalial Carcinoma; SEIC

Summary: background: serous endometrial intra-epithelial carcinoma (seic) is a rare condition affecting the lining of the uterus. it's a pre-cancerous change that might lead to cancer if not treated. doctors aren't sure of the best way to manage it because it's so uncommon. a previous study looked at past cases in the netherlands from 2012 to 2020. this study found that none of the 23 women with seic had their cancer spread during surgery, and none had a recurrence in the following three years. this suggests that a simpler surgery might be safe for patients with seic. methods: information on disease details from patients who agree to participate in our study will be collected. all participants will fill out online forms and health questionnaires at several points: when they join the study, and again at six months, two years, and five years after their diagnosis. during the years after diagnosis, various details like health status, test results, treatments will be checked in the electronic medical record. results: this study is just starting, with the first patients expected to join on january 1, 2025. conclusion: a large international study is created to track seic patients over time. this will help us learn more about the condition and improve treatment strategies.


Eligibility criteria:
inclusion criteria: * serous endometrial intra-epithelial carcinoma (seic). * women older than 18 years of age. * women with understanding of dutch or english language in reading and writing. exclusion criteria: * diagnosis with a different type of endometrial neoplasm or invasive carcinoma. * previous and/or current treatment for another malignancy (\<2 year before diagnosis of seic).

Keywords: sereus endometrial intraepithelial carcinoma seic endometrial cancer premalignant neoplasms
impact of regular consumption of eggs and nutrients fortified eggs on eczema condition in singapore individuals

Conditions: Atopic Dermatitis Eczema; Aging; Diet Modification

Summary: the study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in singapore individuals with eczema. the investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema

this is a double-blind, randomized, parallel study and all subjects will complete a 12-week study period. subjects will be tasked to consume nutrients-fortified eggs and regular eggs daily for 12 weeks. after which, subjects are assessed for changes in carotenoid status, antioxidant and anti-inflammatory biomarkers, skin and eye health measurements, and other biomarkers of health.

Eligibility criteria:
inclusion criteria: 1. english-literate and able to give informed consent in english 2. male and female participants, aged between 21 and 59 inclusive 3. healthy individuals with no underlying condition or on regular medication 4. bmi between 18.5-25 kg/m2 5. mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit exclusion criteria: 1. significant change in body weight (3 kg or more) in the past 3 months 2. significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week 3. known food allergy to eggs 4. taking dietary supplements which may impact the study results 5. having gastrointestinal disorders not suitable for the study 6. current smokers 7. consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider, or 45ml of distilled spirit 8. taking lipid-lowering and blood pressure-controlling medications for less than 3 years 9. pregnant or lactating women, or planning to conceive in the next 6 months 10. unwilling to stop the medication of eczema during the study, either topical creams or oral medications 11. hierarchical link (professional and familial ties) with the research team members 12. participating in another clinical study 13. having blindness in one eye or more, eye diseases, retinal/lens/optical nerve surgery, or other eye conditions that may impact the study results 14. low-quality macular pigment optical density results were determined during the screening visit.

Keywords: atopic dermatitis eczema young and middle-aged adults eye health antioxidants
decline in renal concentration ability in lithium treated patients

Conditions: Lithium Toxicities; Bipolar Disorder; Concentration Ability Impaired; Nephrogenic Diabetes Insipidus; Lithium - Induced Nephropathy

Summary: lithium therapy is cornerstone in therapy of bipolar disorders. a well known side-effect of lithium therapy is a urinary concentration defect which manifests in it's most severe form as nephrogenic diabetes insipidus. the development of urinary concentration defects and its progression to nephrogenic diabetes insipidus in the population of lithium treated patients is unknown and therefore this study aims to evaluate the decline of urinary concentration defects in a dutch population of lithium treated patients. in this prospective cohort study, 51 participants treated with lithium at canisius wilhelmina hospital, nijmegen and included in the previous study in 2012 will be approached to undergo a follow-up ddavp-test.


Eligibility criteria:
inclusion criteria: * included in the previous study * men and women * age ≥ 18 years exclusion criteria: * general contra-indications for participation in a trial: * inability to give informed consent * pregnancy * unstable psychiatric condition * alternative causes of (nephrogenic) diabetes insipidus: * hypokalemia (plasma potassium \< 3.0 mmol/l) * severe hypercalcemia (albumin-corrected plasma calcium \> 2.80 mmol/l) * hyperglycemia (plasma glucose \> 10.0 mmol/l) * history of amyloidosis, sjögren's syndrome or sickle cell anemia * previous treatment with ifosfamide * established primary polydipsia or central diabetes insipidus * contra-indications for ddavp administration: * inability to comply with water restriction * renal insufficiency (gfr \< 45 ml/min/1.73 m2) * hyponatremia (plasma sodium \< 130 mmol/l) * instable angina pectoris * decompensated cardial insufficiency * other: * concomitant treatment with desmopressin or democlocycline
evaluation of filtering blebs using the "wuerzburg bleb classification score" compared to other clinical findings, e.g. the intraocular pressure (iop)

Conditions: Glaucoma

Summary: it is well established to assess the functionality of a filtering bleb by intraocular pressure (iop), either as an absolute value or as a percent reduction, and by the need of additional antiglaucoma drugs. it is also possible to evaluate the appearance of a bleb by a clinical score, e.g. the "wuerzburg bleb classification score" (wbcs). the purpose of this study was to find out whether there is a correlation between clinical findings, in particular iop and the wbcs. 100 eyes within two years after trabeculectomy were included into the study. using colour photographs the filtering bleb was evaluated according to the wbcs from two different examiners, both on different levels of clinical experience. wbcs = 1 indicates poor bleb appearance, wbcs = 15 indicates optimal bleb appearance. at the same time, clinical findings like intraocular pressure, best corrected visual acuity, slit lamp biomicroscopy and medical history were taken by another examiner. * trial with surgical intervention


Eligibility criteria:
inclusion criteria: diagnosis of glaucoma, status post trabeculectomy exclusion criteria: age \<18 jahre, other optic neuropathy than glaucoma
esophageal replacement with a decellularized human esophagus graft

Conditions: Esophageal Stenosis

Summary: the aim of the study is to analyze over a 12 month-period, the safety and the efficacy of a circumferentiel oesophageal replacement of the esophagus by a decelularized human esophagus, in 24 patient with a short esophageal stenosis refractory to endoscopic dilatations.


Eligibility criteria:
inclusion criteria: * age: 18 to 65 * caustic, traumatic, anastomotic, post-operative, radiation-induced or post-endoscopic (mucosal resection, submucosal dissection) benign esophageal stricture refractory to endoscopic dilatation. * for women: effective contraception for the entire duration of the study (from signature of consent to end of follow-up) * affiliated or beneficiary of a social security scheme. * free written consent signed by the participant and the investigator. exclusion criteria: * weight loss \> 10% of body weight over last 3 months * stenosis \> 5 cm in length * multiple strictures * esophageal mouth stenosis * anterior surgery close to the operative zone * complete anterior omentectomy * tumour stenosis or progressive tumour pathology * non-stabilized psychiatric disorders * participation in another interventional study * pregnant or breast-feeding women * women of childbearing age without effective contraceptive measures: all women of childbearing age must have a negative pregnancy test prior to treatment and must agree to maintain highly effective contraception using contraceptive measures from the date of consent until 12 months due to the risks associated with anesthesia during endoscopy * uncontrolled sepsis * related to the transplant procedure * asa score ≥ 3, * severe respiratory insufficiency (fev1 \< 1 l), * decompensated hepatic cirrhosis or presence of esophageal varices, * chronic renal insufficiency (creatinine \> 1.25 n), * myocardial infarction less than 6 months old or progressive heart disease, * who general condition \> 2, * weight loss \>20% not recovered after renutrition. * contraindication to general anaesthesia, analgesics and antibiotics. * conditions requiring long-term immunosuppressive or corticosteroid treatment. * patients under curatorship or guardianship

Keywords: tissue engineering esophageal replacement esophageal stenosis caustic injury radiotherapy anastomotic stenosis esophageal stent
lipid based food additives for treating patients with dry mouth

Conditions: Xerostomia

Summary: over 10% of adult population suffers from dry mouth (xerostomia). the aim of this double blind prospective clinical trial is to examine a new lipid based food additive formulation to ease mouth dryness in these patients.


Eligibility criteria:
inclusion criteria: * dry mouth patients exclusion criteria: * disabled patients * pregnant * full upper denture * under 18 years old
efficacy of silymarin in patients with non-alcoholic fatty liver disease - the siliver trial

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: non-alcoholic fatty liver disease (nafld) is one of the most prevalent chronic liver diseases in brazil and its treatment is still limited. thus, this project aims to conduct a double-blind, controlled, randomized clinical trial to evaluate the effect of silymarin on laboratory markers and clinical evolution of adult patients with nafld treated at edgard santos hospital, as well as identify the dietary pattern of these individuals.

non-alcoholic fatty liver disease (nafld) is one of the most prevalent chronic liver diseases in brazil. it has a significantly increasing incidence today and is considered an important global health problem. it affects approximately 20 to 30% of the adult population and increases according to the severity of the risk factors. the diagnosis of this disease usually occurs in 10 to 20% of the non-obese individuals, 50% in the overweight and 80 to 90% in the obese, being twice as present in individuals with metabolic syndrome. pharmacological treatment options for nafld are still limited and silybum marianum, one of the most sought-after herbal remedies in patients with liver disease, is commonly used by patients because of the claim of the hepatoprotective effect of silymarin. studies have demonstrated the therapeutic potential of silymarin in patients with nafld, but clinical trials with more judicious methodological designs is still needed to prove these effects. thus, this project aims to evaluate the efficacy of silymarin in adult patients with nafld seen at the clinic of nutrition and hepatology of edgard santos hospital. a randomized, double-blind, controlled clinical trial lasting 12 weeks will be performed.

Eligibility criteria:
inclusion criteria: * adults between 20 and 60 years of age, both men and women, * clinical diagnosis of nafld, confirmed by imaging exams, exclusion criteria: * women in the menacing period, with the exception of those who have performed definitive sterilization, such as hysterectomy or tubal ligation. * patients with established prior diagnosis of chronic noncommunicable disease (congestive heart failure, decompensated or severe lung disease, neoplasms, renal disease, advanced liver disease - child pugh c classification) * patients with schistosomiasis; * hemochromatosis * wilson's disease * viral or autoimmune hepatitis * hiv virus carriers * woman who is breastfeeding * users of illicit drugs * patients with an intake of more than 20 g / day of alcohol and / or past alcoholism with abstention less than 6 months; * patients with ingestion of medications such as steroids, estrogens, amiodarone, warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents in the last 6 months * patients with clinically manifest infections or inflammation, surgery, trauma or hospitalization in the last 30 days * chronic non-hepatic degenerative diseases (sclerosis, parkinson's disease or alzheimer's disease) * patients who do not participate in all stages of the research.

Keywords: non-alcoholic fatty liver disease sylimarin
modified dynamic needle tip positioning vs conventional long-axis in-plane in radial artery cannulation

Conditions: Ultrasound; Arterial Catheterization; Coronary Artery Disease

Summary: conventionally, long-axis in-plane (la-ip), short-axis out-of-plane (sa-oop) and dynamic needle tip positioning based on sa-oop views are commonly used method to image the target vessel during cannulation under us guidance. a modified sa-oop that add developing line on the ultrasonic probe improve the success rate of cannula insertion into the radial artery on the first attempt.


Eligibility criteria:
inclusion criteria: 1. the diagnostic criteria of coronary atherosclerotic heart disease according to the tenth version of international classification of diseases(icd-10); 2. requires invasive arterial blood pressure monitoring; 3. new york heart association(nyha) classification i, ii or iii; 4. the american society of anesthesiologists (asa) classification i, ii or iii; 5. patients older than 18 years and younger than 85 years (adult); 6. patients signed the informed consent before the study. exclusion criteria: 1. patients with hemodynamically unstable (systolic blood pressure 60 or less); 2. patients with abnormal results of the modified allen test; 3. patients with ulnar artery occlusion; 4. patients with coagulation disorders; 5. patients with skin abnormalities such as inflammation or hematoma at the cannulation site; 6. patients with raynaud disease and prevalent atherosclerosis; 7. patients with history of hand or wrist trauma or surgery; 8. patients who have undergone radial artery interventional therapy or radial artery cannulation within 3 months on the puncture side; 9. patients with bmi more than 40 kg/m2; 10. patients who have participated in other relevant clinical studies within 3 months.
impact of anti-static chamber/mask

Conditions: Asthma

Summary: to compare lung delivery of fluticasone propionate delivered by hfa-pmdi, using a conventional polycarbonate of anti-static chamber/mask in a randomized crossover design in 1-6 year old children. hypothesis: anti-static chamber/mask would increase the amount of inhaled corticosteroid delivered to young children who passively inhale and cannot breath hold.

objective -- to determine whether an anti-static chamber increases the one-hour steady-state fluticasone plasma concentration, which is an indirect measure of airway delivery and direct measure of systemic exposure. twelve children 1-6 yrs with well-controlled persistent asthma were treated with hfa-fp pmdi, 2 actuations of 110 µg twice daily. the drug was administered by conventional polycarbonate or anti-static valved-holding chambers with masks in an unblinded, randomized, crossover manner each for at least three days. a blood sample was collected one hour after the last dose when adherence documented by electronic monitor was 100%. fp plasma concentrations were measured by liquid chromatography mass spectrometry assay. results evaluated using regression analysis.

Eligibility criteria:
inclusion criteria: * children 1-6 years old; adequately controlled persistent asthma; currently receiving fp delivered by cfc mdi attached to valved-holding chamber/mask; ability to use chamber with mask effectively exclusion criteria: * inadequately controlled asthma: nocturnal awakening \> 2 nights/month, prn albuterol use \> 2x/week, more than 2 short courses of oral corticosteroids in previous 3 months, missing a dose on more than one occasion, increase in asthma symptoms during study, inability to discontinue intranasal or dermal fluticasone for 3 days

Keywords: fluticasone asthma therapy spacer inhaler hfa-134a
effect of rtms on the abnormal executive function of asd children

Conditions: Executive Dysfunction; ASD

Summary: in this study, the investigators will explore the effects of repetitive transcranial magnetic stimulation (rtms) on executive function deficits in high function autism spectrum disorder. half of the participants will be chosen by chance to receive continuous theta burst stimulation (ctbs) while the other half will be chosen by chance to receive sham stimulation. and finally the sham group individuals also receive ctbs. based on results from a recent unpublished pilot data, the investigators propose that ctbs treatment will induce a significant improvement in executive function performance compared to sham treatment.

this study is a randomized, sham controlled study to evaluate the efficacy of ctbs as a treatment for executive function deficits in individuals with autism spectrum disorder between 6 and 16 years of age. the study duration is approximately 1 months, with the ctbs sessions lasting for 4 weeks, 5 times a week, for about 20min each. several scales will be used to assess for symptom severity and adaptive functioning. the executive function will be evaluated by behaviour rating inventory of executive functioning (brief) questionnaire. cognition will be assessed using functional near - infrared spectroscopy (fnirs). this study also involves a type of brain imaging known as magnetic resonance imaging (mri) at the beginning and at the end of the 4 weeks daily ctbs to better understand the effects of ctbs on brain structure and function. investigators will measure the size and connections of different parts of the brain to assess brain structure and blood flow.

Eligibility criteria:
inclusion criteria: * patients diagnosed with asd. diagnostic criteria: diagnosed by pediatric psychiatrists in accordance with the criteria in the fifth edition of diagnostic and statistical manual of mental disorders (dsm-v), autism diagnostic observation schedule (ados) and autism diagnostic interview-revised (adi-r); * have a diagnosis of high functioning asd (hf-asd) (i.e., are verbal with an intelligence quotient (iq) ≥ 70) * are clinically stable as determined by their treating physician, with no medication changes over the past 4 weeks exclusion criteria: * have metal or electronic instruments near the stimulation brain area of coil, such as, have intravascular stent in head, have metal objects in skull. * have cardiac pacemaker, cochlear implant, medical pump; * can not cooperate with examiner; * have intracranial foreign bodies by craniotomy, or intracranial deformity * have a history of substance abuse or dependence in the last 6 months or have a positive urine toxicology screen * have a concomitant major medical or neurologic illness * have had a seizure in the past, or have a first-degree relative with epilepsy * have an abnormal clinical eeg * are pregnant or likely to get pregnant during the next 4 weeks * have a history of rtms treatment.
microvascular ultrasonographic imaging for the detection of early stage epithelial ovarian carcinoma

Conditions: Ovarian Neoplasms

Summary: in the united states, ovarian cancer is the fifth most common cancer to develop in women and causes more deaths than all other gynecologic malignancies combined. because of the difficulties in detecting early stage ovarian cancer, 75% of women continue to be diagnosed with advanced stage disease (stage iii or iv). the national ovarian cancer early detection program (nocedp) as part of the national cancer institute's early detection research network (edrn) is committed to the development of effective means for the accurate detection of early stage ovarian cancer. the last decade has seen rapid technological advances in diagnostic ultrasonography with the recent development of three-dimensional imaging. initial studies suggest that these new technologies improve upon the diagnostic accuracy of two-dimensional transvaginal imaging in the differentiation between benign and malignant pathology. this improved diagnostic accuracy may promote improved patient care by separating complex benign masses from ovarian cancer therefore facilitating appropriate treatment.


Eligibility criteria:
inclusion criteria: 1. women must be greater than 21 years of age 2. women must have a complex adnexal mass (as defined per ultrasound) which requires surgical intervention exclusion criteria: 1. known or suspected hypersensitivity to blood, blood products, or albumin. 2. known history of congenital heart defect that creates a bi-directional or right-to-left shunt. 3. known history of severe emphysema or a history of pulmonary emboli. 4. known history of severe pulmonary hypertension (systolic pulmonary artery pressures \> 90 mmhg).

Keywords: women with ultrasound defined complex pelvic masses
the effectiveness of continuous ketamine infusion (kontinue)

Conditions: Chronic Pain

Summary: there are different treatment for chronic pain. one possible treatment is intravenous infusions of ketamine.

ketamine continuous intravenous infusion for 4 days in hospital with 0.5 mg/kg/day associated with magnesium sulfate 1000mg/day. evaluation schedules will be performed at day 15,30 and 60.

Eligibility criteria:
inclusion criteria: - pain lasting for more than six months without contraindication to treatment exclusion criteria: * inability to give consent * severe psychiatric disorder

Keywords: pain neuropathic pain chronic pain fibromyalgia musculoskeletal diseases
prevalence of sonographic abnormalities of joints and entheses in psoriasis patients with or without musculoskeletal complains

Conditions: Psoriasis

Summary: the objectives of this study are: * to estimate the prevalence and severity of inflammatory (synovitis, tenosynovitis, enthesitis, dactylitis) and structural (erosions, osteophytes, enthesophytes, cortical irregularities ) ultrasound lesions in psoriasis patients with or without related musculoskeletal symptoms; * to compare them to healthy subjects or patients suffering from rheumatoid arthritis and osteoarthritis.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * psoriasis diagnosed by a dermatologist; * able to participate in the study; * informed consent signed. exclusion criteria: - chronic disease likely to cause musculoskeletal symptoms (connective tissue diseases, inflammatory bowel diseases, overload disorders, crystal related arthritis, septic arthritis...).

Keywords: psoriasis psoriatic arthritis ultrasound